DBV 1605
Alternative Names: DBV-1605Latest Information Update: 26 Dec 2022
At a glance
- Originator DBV Technologies
- Class Protein diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Milk hypersensitivity
Most Recent Events
- 26 Dec 2022 Phase-II development is ongoing in Milk hypersensitivity (Diagnosis, In children) in USA, Lithuania, Canada and Italy (Topical) (NCT04492683)
- 28 Oct 2020 Phase-II clinical trials in Milk hypersensitivity (Diagnosis, In children) in Lithuania (Topical) (EudraCT2019-004523-21)
- 28 Aug 2020 Phase-II clinical trials in Milk hypersensitivity (Diagnosis, In children) in Italy, Canada (Topical) (NCT04492683)